Loading...

Genetic Signatures Limited

GSS.AX•ASX
HealthcareMedical - Diagnostics & Research
A$0.43
A$-0.01(-2.27%)

Genetic Signatures Limited (GSS.AX) Stock Overview

Explore Genetic Signatures Limited’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-42.35%
↓ 42.35%
Profit Growth
A$-0.10
↓ 27.11%
EPS Growth
A$-0.10
↓ 14.94%
Operating Margin
-115.13%
↓ 18.22%
ROE
-39.06%
↓ 27.11%
Dividend Yield
0.00%
Analyst Recommendations data is not available for GSS.AXAnalyst Recommendations details for GSS.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.

CEO

Ms. Allison Rossiter

Headquarters

Heart Research Institute, Newtown, NSW

Founded

2015

Frequently Asked Questions